Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Progesterone for Prevention of Preterm Birth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01180296
Recruitment Status : Completed
First Posted : August 12, 2010
Results First Posted : July 21, 2011
Last Update Posted : February 18, 2019
Sponsor:
Information provided by (Responsible Party):
David S. McKenna, Fetal Medicine Foundation

Brief Summary:
To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.

Condition or disease Intervention/treatment Phase
Preterm Birth Drug: oral micronized progesterone Drug: Identical Placebo tablet Phase 3

Detailed Description:
To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prevention of Recurrent Preterm Birth With Micronized Progesterone
Study Start Date : November 2006
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Progesterone Group
Oral Micronized Progesterone
Drug: oral micronized progesterone
oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
Other Name: Prometrium(TM)

Placebo Comparator: Placebo
Identical Placebo Tablet
Drug: Identical Placebo tablet
Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
Other Name: Placebo




Primary Outcome Measures :
  1. Rate of Recurrent Preterm Birth [ Time Frame: Prior to 37 weeks' gestation ]
    Spontaneous preterm birth prior to 37 weeks' gestation. Indicated preterm deliveries (for maternal or fetal reasons) were excluded.


Secondary Outcome Measures :
  1. Secondary Outcomes [ Time Frame: Mean +/- Std Dev gestational age of 25.9/-2.4 weeks in Progesterone group, and 28.4 +/-4.7 weeks in placebo group ]
    Serum progesterone levels



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 & 0/7 weeks' and 36 & 6/7 weeks' gestation.

Exclusion Criteria:

  • multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01180296


Locations
Layout table for location information
United States, Ohio
Miami Valley HospitaL
Dayton, Ohio, United States, 45409
Sponsors and Collaborators
Fetal Medicine Foundation
Investigators
Layout table for investigator information
Principal Investigator: David S McKenna, MD Fetal Medicine Foundation/USA
Layout table for additonal information
Responsible Party: David S. McKenna, PI, Fetal Medicine Foundation
ClinicalTrials.gov Identifier: NCT01180296    
Other Study ID Numbers: MVH-MP-Pilot-RCT
First Posted: August 12, 2010    Key Record Dates
Results First Posted: July 21, 2011
Last Update Posted: February 18, 2019
Last Verified: February 2019
Keywords provided by David S. McKenna, Fetal Medicine Foundation:
Preterm birth, prevention, progesterone, oral
Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Progesterone
Progestins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs